These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8621273)

  • 1. Resistance mechanisms in human lung cancer.
    Mattern J; Volm M
    Invasion Metastasis; 1995; 15(3-4):81-94. PubMed ID: 8621273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance in cancer: a multifactorial problem.
    Mattern J
    Anticancer Res; 2003; 23(2C):1769-72. PubMed ID: 12820456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of drug resistance in breast cancer.
    Dalton WS
    Semin Oncol; 1990 Aug; 17(4 Suppl 7):37-9. PubMed ID: 2200130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance mechanisms in cancer cells: a proteomics perspective.
    Verrills NM; Kavallaris M
    Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines.
    Gariboldi MB; Ravizza R; Riganti L; Meschini S; Calcabrini A; Marra M; Arancia G; Dolfini E; Monti E
    Int J Oncol; 2003 May; 22(5):1057-64. PubMed ID: 12684672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
    Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting senescence pathways to reverse drug resistance in cancer.
    Rebbaa A
    Cancer Lett; 2005 Feb; 219(1):1-13. PubMed ID: 15694659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of drug resistance.
    Longley DB; Johnston PG
    J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of lung-resistance protein gene is not associated with platinum drug exposure in lung cancer.
    Oguri T; Fujiwara Y; Ochiai M; Fujitaka K; Miyazaki M; Takahashi T; Yokozaki M; Isobe T; Ohune T; Tsuya T; Katoh O; Yamakido M
    Anticancer Res; 1998; 18(6A):4159-62. PubMed ID: 9891461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.
    Tomida A; Tsuruo T
    Anticancer Drug Des; 1999 Apr; 14(2):169-77. PubMed ID: 10405643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
    Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
    Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
    Deng HB; Adikari M; Parekh HK; Simpkins H
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
    Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
    Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
    Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.